This analysis in RR MCL shows CAR T-cell therapy (brexucabtagene) yields higher complete responses vs bispecific antibodies; durability remains unclear.
|Articles|October 1, 1996
The American Journal of Managed Care
- October 1996
- Volume 2
- Issue 9
Estimating Prevalence and Detection Cost: Prerequisites for Disease State Management of Attention Deficit Hyperactivity Disorder
Author(s)Edward T. Heck, PhD
Advertisement
Articles in this issue
about 30 years ago
The Influence of New Devices on the Costs of Interventional Proceduresabout 30 years ago
Patterns of Antidepressant Use and Their Relation to Costs of Careabout 30 years ago
The Psychopharmacology of Depression in the Managed Care Settingabout 30 years ago
Cost-Effective Treatment of DepressionAdvertisement
Related to this article
The Ambulatory Specialty Model aims to reduce chronic disease costs by mandating specialist participation and tying payments to quality and cost, while posing nationwide risk challenges.
Medicare drug price negotiations lowered out-of-pocket costs for some beneficiaries, but those reaching the annual Part D cap saw no direct savings.
AI quantitative CT (UCLA QILD, Brainomix e-Lung) predicts FVC decline and drug response in PPF, strengthening biomarkers beyond spirometry in INBUILD.
Delphi consensus guides dermatology on spotting CTCL vs atopic dermatitis before/after dupilumab, using biopsy plus T-cell clonality testing and safer treatment switches.
Rosacea is likely missed, not rare, in skin of color, as low suspicion and hard-to-see redness delay diagnosis, said Hilary Baldwin, MD.
Hidradenitis suppurativa diagnosis often takes 7 to 10 years, and patients with skin of color often present with tunnels and scarring already in place.
In HIV, lymphoma survival tracks tumor stage and CD4 count, not viral suppression, a Spanish cohort shows.
Advertisement
Advertisement
Trending on AJMC
1
Medicare Drug Price Negotiations Yield Uneven Out-of-Pocket Savings
2
Lymphoma Outcomes Hinge on Oncology, Not Viral Load In People With HIV
3
New Mechanism of DME Treatment Highlights Clinical Trial Updates
4
Rusfertide Keeps Working Where Hydroxyurea Fades: Andrew Kuykendall, MD
5